United Therapeutics Corporation (NASDAQ:UTHR) Stock Has Average Target Price of $674.00 According to Brokerages

Key Points

• Analysts rate United Therapeutics a “Moderate Buy”, with 13 Buy, two Hold and one Sell recommendations among 16 firms; the average 12-month price target is $674. BTIG raised its target to $768.
• Third-quarter revenue rose 4.1% year over year to $832.5 million, beating estimates, while EPS of $5.71 missed the $6.01 consensus and declined from $7.16 a year earlier.
• The board authorized a $2 billion share-repurchase plan, allowing the company to buy back up to 8.3% of its shares.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) has earned an average rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $674.00.

UTHR has been the subject of several recent research reports. BTIG Research boosted their target price on shares of United Therapeutics from $728.00 to $768.00 and gave the company a "buy" rating in a research note on Wednesday. UBS Group set a $725.00 price target on United Therapeutics in a report on Monday, October 19th. Jefferies Financial Group restated a "buy" rating and issued a $728.00 target price on shares of United Therapeutics in a research report on Wednesday, October 14th. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Finally, The Goldman Sachs Group reaffirmed a "sell" rating and set a $368.00 price objective on shares of United Therapeutics in a research note on Thursday, October 15th.

United Therapeutics Trading Up 1.2%

Shares of NASDAQ:UTHR opened at $608.49 on Thursday. The company has a fifty day simple moving average of $532.33 and a 200 day simple moving average of $532.45. The firm has a market cap of $26.10 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.49. United Therapeutics has a 12-month low of $432.53 and a 12-month high of $614.23.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same period in the previous year, the business posted $7.16 EPS. The business's revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its board has authorized a stock repurchase plan on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Share buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. Management said the company is entering a period of stronger growth and advancing new therapies. United Therapeutics Q3 2026 results
• Positive Sentiment: BTIG raised its price target to $768 from $728 and maintained a Buy rating, signaling continued analyst confidence in the shares. BTIG Research ratings
• Positive Sentiment: The company announced a buyout of Pfizer’s royalty rights tied to ralinepag, a lung-disease therapy. Ending those royalties could improve the drug’s future economics, though the announcement details provided no financial terms. Ralinepag royalty buydown announcement
• Negative Sentiment: Adjusted earnings were a weak spot: EPS of $5.71 missed the approximately $6.01 consensus and fell from $7.16 a year earlier. Reports also noted lower net income. Q3 earnings miss
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, reducing her direct holding by 2.84%. She retained 324,443 shares; the sale may draw investor attention but does not by itself establish a change in the company’s outlook. United Therapeutics insider trades

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $596.22, for a total transaction of $5,664,090.00. Following the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at $193,439,405.46. The trade was a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,587,119.60. This represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 393,228 shares of company stock valued at $207,340,321. Company insiders own 8.60% of the company's stock.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. New York Life Investment Management LLC grew its stake in shares of United Therapeutics by 7.0% in the third quarter. New York Life Investment Management LLC now owns 1,106 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 72 shares during the last quarter. Gen Wealth Partners Inc bought a new stake in United Therapeutics in the 3rd quarter valued at $34,000. Gryphon Financial Partners LLC boosted its holdings in United Therapeutics by 3.7% in the 3rd quarter. Gryphon Financial Partners LLC now owns 1,650 shares of the biotechnology company's stock valued at $894,000 after purchasing an additional 59 shares during the period. Leuthold Group LLC grew its position in United Therapeutics by 9.3% in the 3rd quarter. Leuthold Group LLC now owns 11,132 shares of the biotechnology company's stock worth $6,032,000 after purchasing an additional 948 shares during the last quarter. Finally, Retirement Systems of Alabama grew its position in United Therapeutics by 0.4% in the 3rd quarter. Retirement Systems of Alabama now owns 89,832 shares of the biotechnology company's stock worth $48,679,000 after purchasing an additional 336 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.